Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26377827 | 0.89 | GAA (0.83) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL5534089 | 0.86 | GAA (0.74) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL6777737 | 0.85 | L3MBTL1 (0.57) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL7767632 | 0.84 | L3MBTL1 (0.56) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL5533585 | 0.83 | L3MBTL1 (0.69) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL12085534 | 0.82 | L3MBTL1 (0.69) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL1930296 | 0.80 | MEN1 (0.70) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 | |
| SCHEMBL976467 | 0.78 | TSHR (0.68) | L3MBTL1HDAC6HDAC1GAAMEN1 | |
| SCHEMBL352886 | 0.78 | TSHR (0.68) | L3MBTL1GAAMEN1KMT2ATSHR | |
| Oxirane SCHEMBL6772854 | 0.78 | L3MBTL1 (0.61) | L3MBTL1HDAC6HDAC1HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018139-A1 | NEW SMALL-MOLECULE COMPOUNDS FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTORS AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | S＆K THERAPEUTICS (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-4253382-A1 | NEW SMALL-MOLECULE COMPOUND FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTOR AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | S&K Therapeutics (KR) | 2023-10-04 | — | — | EP | disclosed |
| CN-116507329-A | Novel small molecule compounds for controlling endosomal Toll-like receptor and therapeutic agent for autoimmune disease using the same | S和K 疗法公司 | 2023-07-28 | — | — | CN | disclosed |
| US-6680319-B2 | TREATMENT OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA, TREATMENT OF LOWER URINARY TRACT SYMPTOMS | RECORDATI S.A. (CH) | 2004-01-20 | — | — | US | disclosed |
| EP-1226131-B1 | ISOXAZOLECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183290-A1 | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-05 | — | — | US | disclosed |
| US-20020161012-A1 | Isoxazolecarboxamide derivatives | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002060534-A2 | SELECTIVE ALPHA 1 ANTAGONISTS A + D | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2002-08-08 | — | — | WO | disclosed |
| US-6365591-B1 | FOR THERAPY OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA (BPH), AND IN THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND NEUROGENIC LOWER URINARY TRACT DYSFUNCTION (NLUTD) | RECORDATI, S.A., CHEMICAL AND PHARMACUETICALS COMPANY (CH) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018139-A1 | NEW SMALL-MOLECULE COMPOUNDS FOR CONTROLLING ENDOSOMAL TOLL-LIKE RECEPTORS AND THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES USING SAME | TLR9, TLR8, TLR3 | L3MBTL1 1259/4885HDAC6 799/4885HDAC1 1684/4885 |
| US-20020183290-A1 | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | ADRB1, ADRA1D, ADRA1B | L3MBTL1 1517/4885HDAC6 4348/4885HDAC1 3152/4885 |
| US-20020161012-A1 | Isoxazolecarboxamide derivatives | ADRA1D, NMUR1, NMUR2 | L3MBTL1 1977/4885HDAC6 1537/4885HDAC1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.